Stability over 36 months of a new liquid 10% polyclonal immunoglobulin product (IgPro10, Privigen) stabilized with L-proline

Vox Sanguinis

Volumn 96, Issue 3, 2009, Pages 219-225

  Cramer, M ^a   Frei, R ^a   Sebald, A ^a   Mazzoletti, P ^a   Maeder, W ^a  

^a CSL Behring AG   (Switzerland)

Author keywords

Dimer; Igpro10 (privigen); Intravenous immunoglobulin; L proline; Stability

Indexed keywords

IMMUNOGLOBULIN G; POLYCLONAL ANTIBODY; PRIVIGEN; PROLINE; UNCLASSIFIED DRUG;

ARTICLE; DRUG DETERMINATION; DRUG STABILITY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; PH; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; SHELF LIFE; TEMPERATURE DEPENDENCE;

HOT TEMPERATURE; HUMANS; HYDROGEN-ION CONCENTRATION; IMMUNOGLOBULINS, INTRAVENOUS; PRESERVATION, BIOLOGICAL; PROLINE; PROTEIN STABILITY; TIME FACTORS;

EID: 62349139717     PISSN: 00429007     EISSN: 14230410     Source Type: Journal    
DOI: 10.1111/j.1423-0410.2008.01143.x     Document Type: Article

References (29)

1. Jolles S, Sewell WAC, Misbah SA : Clinical uses of intravenous immunoglobulin. Clin Exp Immunol 2005 142 : 1 11
2. Bonilla FA, Bernstein IL, Kahn DA, Ballas ZK, Chinen J, Frank MM, Kobrynski LJ, Levinson AI, Mazer B, Nelson RP, Orange JS, Routes JM, Shearer WT, Sorensen RU : Practice parameter for the diagnosis and management of primary immunodeficiency. Ann Allergy Asthma Immunol 2005 94 : S1 S63
3. Stiehm ER : Human intravenous immunoglobulin in primary and secondary antibody deficiencies. Pediatr Infect Dis J 1997 16 : 696 707
4. Misra N, Bayry J, Ephrem A, Dasgupta S, Delignat S, Van Huyen JP, Prost F, Lacroix-Desmazes S, Nicoletti A, Kazatchkine MD, Kaveri SV : Intravenous immunoglobulin in neurological disorders: a mechanistic perspective. J Neurol 2005 252 : I1 I6
5. Lemm G : Composition and properties of IVIg preparations that affect tolerability and therapeutic efficacy. Neurology 2002 59 : S28 S32
6. Gelfand EW : Critical decisions in selecting an intravenous immunoglobulin product. J Infus Nurs 2005 28 : 366 374
7. Daugherty AL, Mrsny RJ : Formulation and delivery issues for monoclonal antibody therapeutics. Adv Drug Delivery Rev 2006 58 : 686 706
8. Knezevic-Maramica I, Kruskall MS : Intravenous immune globulins: an update for clinicians. Transfusion 2003 43 : 1460 1480
9. Wang W : Instability, stabilization, and formulation of liquid protein pharmaceuticals. Int J Pharm 1999 185 : 129 188
10. Rosenberg AS : Effects of protein aggregates: an immunologic perspective. AAPS J 2006 8 : E501 E507
11. Tankersley DL : Dimer formation in immunoglobulin preparations and speculations on the mechanism of action of intravenous immune globulin in autoimmune diseases. Immunol Rev 1994 139 : 159 172
12. Bleeker WK, Teeling JL, Verhoeven AJ, Rigter GMM, Agterberg J, Tool ATJ, Koenderman AHL, Kuijpers TW, Hacket CE : Vasoactive side effects of intravenous immunoglobulin preparations in a rat model and their treatment with recombinant platelet-activating factor acetylhydrolase. Blood 2000 95 : 1856 1861
13. Kroez M, Kanzy EJ, Gronski P, Dickneite G : Hypotension with intravenous immunoglobulin therapy: importance of pH and dimer formation. Biologicals 2003 31 : 277 286
14. Bolli R, Spycher MO, Brügger R, Wüst B, Gennari K : IgG-dimer formation in liquid immunoglobulin preparations is inhibited by nicotinamide and other amphiphilic compounds. J Autoimmun 1999 96 (Suppl. 1 96
15. Kistler P, Nitschmann H : Large scale production of human plasma proteins. Vox Sang 1962 7 : 414 424
16. Cohn EJ, Strong LE, Hughes WI, Jr., Mulford DJ, Asworth JN, Melin M, Taylor HL : Preparation and properties of serum and plasma proteins. IV. A system for the separation into fractions of the protein and lipoprotein components of tissues and fluids. J Am Chem Soc 1946 68 : 459 475
17. International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use: Q5C : Quality of Biotechnological Products: Stability Testing of Biotechnological/Biological Products. 30 November 1995; available at http://www.ich.org/LOB/media/MEDIA427.pdf
18. International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use: Q1A (R2) : Stability Testing of New Drug Substances and Products. 6 February 2003; available at http://www.ich.org/LOB/media/MEDIA419.pdf
19. Sebald A, Schermbach M, Maeder W : Comparison of two distinct methods for assessing the requirements of the Ph.Eur. concerning discolouration during 36 months stability studies for a new liquid polyvalent immunoglobulin product. The Fifth Plasma Product Biotechnology Meeting 2007, ELBA IT; available at http://www.bo-conf.com/ppb07/index.htm
20. International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use: Q1E : Evaluation for Stability Data. 6 February 2003; available at http://www.ich.org/LOB/media/MEDIA415.pdf
21. Gelfand EW : Differences between IGIV products: impact on clinical outcome. Int Immunopharmacol 2006 6 : 592 599
22. Octapharma USA, Inc Octagam® [Immune globulin intravenous (human) 5% solvent/detergent treated]. Product Information. March 2007; available at http://www.octapharma.com/USA/documents/Octagam%20PI%2030th%20March%202007.pdf
23. Grifols Biologicals, Inc. : Flebogamma® 5% [Immune globulin intravenous (human)]. Product Information November 2006; available at http://www.grifolsusa.com/pdfs/flebo.pdf
24. Talecris Biotherapeutics, Inc. : Gamunex® [Immune globulin intravenous (human) 10% caprylate/chromatography purified]. Product Information. November 2005; available at http://www.fda.gov/CbER/label/gamunexlb.pdf
25. ZLB Behring UK Ltd : Sandoglobulin NF Liquid 12% solution [Human normal immunoglobulin (IVIG)]. Product Monograph. January 2006; available at http://www.csl.com.au/docs/453/434/PI%20V%202.pdf
26. Baxter Healthcare Corporation : Gammagard® [Liquid Immune Globulin Intravenous (Human)] 10%. Product Information. April 2005; available at http://www.baxter.com/products/biopharmaceuticals/downloads/gamliquid-PI.pdf?WT. svl=BiosciencePls&site=www.gammagardliquid.com
27. Teschner W, Butterweck HA, Auer W, Muchitsch E-M, Weber A, Liu S-L, Wah P-S, Schwarz H-P : A new liquid, intravenous immunoglobulin product (IGIV 10%) highly purified by a state-of-the-art process. Vox Sang 2007 92 : 42 55
28. Tankersley DL, Preston MS, Finlayson JS : Immunoglobulin G dimer: an idiotype-anti-idiotype complex. Mol Immunol 1988 25 : 41 48
29. International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use : Q1B: Photostability Testing on New Drug Substances and Products. 6 November 1996; available at http://www.ich.org/LOB/media/MEDIA412.pdf